Caroline is founder and Chief Executive Officer of Elasmogen.

With postgraduate qualifications in both business and science, Caroline has a strong commercial, bio-partnering and biologics drug discovery/development background.  She has successfully led teams at Wyeth Inc and subsequently Pfizer Inc in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc. She is a member of the Opportunity North East Life Sciences Board, a member of the GVV board committed to investing in women’s health, is a Senior Associate for the Entrepreneurial Business School, Edinburgh and holds an honorary Professorship from Queen’s University Belfast having previously been their Entrepreneur in Residence.

She has been awarded a prestigious Royal Society of Edinburgh commercialisation Fellowship and is a doctoral graduate from the University of Aberdeen in Biochemistry and has an MBA from Robert Gordon University.

Andy is one of the founders of Elasmogen and as CTO manages the company’s extensive patent portfolio and IP strategy.

He also holds a number of Non-Exec positions in Life Science and other businesses in Scotland. Andy is part-time Professor of Medical Biotechnology and Director of the Scottish Biologics Facility, University of Aberdeen.

Since 2005 he has been a Fellow of the Royal Society of Edinburgh and until recently was VP Business.

Andy has worked with academics and companies across the world, developing biologics to a range of diagnostic and therapeutic targets including: oncology, inflammation, CNS disease and most recently Covid-19.

Andy is a graduate of St Andrews University.

Dr Savvas Neophytou is partner at Deepbridge Capital LLP where he heads up the firm’s Life Sciences business. Savvas also co-founded Acorn Partners, a joint venture between Deepbridge Capital, Alder Hey Hospital and software engineers WeAreNova.

He is a founding shareholder of a number of technology companies including Torafugu Tech and Cerneretec. Torafugu is engaged in the emerging field of data driven enablers to improve health outcomes and Cerneretec is engaged in the development of point of care diagnostics for the acute care hospital setting. He has also been CEO of Now Healthcare Group, an online doctor platform where he was part of the original team that set up Europe’s largest telehealth platform.

Prior to that Savvas had a long career in the City, working for 15 years as an investment banker and ECM at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald and Panmure Gordon. Sav holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.

Lucy is an investor in BGF’s early stage team, with a focus on life sciences. BGF is a £2.5bn fund supporting earlier stage and established private businesses, and smaller listed companies in the UK.

Lucy’s main role is to source and execute new investments, as well as supporting a number of investee companies at board level. She works across the life sciences space, but has a particular interest in drug discovery platforms.

Prior to BGF, Lucy spent five years in strategy consulting at CIL where she focused on healthcare and pharma. Lucy holds a first class degree in History from Durham University and a Master’s degree in Russian & Eastern European History from Oxford University.

Rod has over 30 years’ experience in the life science industry across both biotech and large pharma.

He has founded three innovative biopharmaceutical companies. As the CEO he has led VHsquared Ltd, PharmaKodex Ltd and Microscience Plc from scientific concept/start up through growth into clinical R&D businesses, raising equity financing while building enterprise value and steering their subsequent successful acquisitions by US and European biopharmaceutical companies.

Prior to this Rod held senior R&D and Commercial management positions at both Glaxo and SmithKline Beecham, heading up Business Development at Glaxo Welcome in the lead up to the formation of GSK.

He is an experienced non-executive Board director having previously held non exec roles at life science companies TdeltaS Ltd and Auralis Ltd and is a former Board member of the UK BioIndustry Association (BIA).

Rod is a graduate of London University with a B.Sc. in Pharmacology

Andy was one of the founders of Elasmogen and as CTO manages the company’s extensive patent portfolio and IP strategy.

He also holds a number of Non-Exec positions in Life Science and other businesses in Scotland. Andy is part-time Professor of Medical Biotechnology and Director of the Scottish Biologics Facility, University of Aberdeen.

Since 2005 he has been a Fellow of the Royal Society of Edinburgh and until recently was VP Business.

Andy has worked with academics and companies across the world, developing biologics to a range of diagnostic and therapeutic targets including: oncology, inflammation, CNS disease and most recently Covid-19.

Andy is a graduate of St Andrews University.

Rob brings over 25 years of drug development experience. He was VP of product development at ILC therapeutics. He was previously the Senior Director of Preclinical at MiroBio.

Before this, Robert worked at Oxford Biotherapeutics, where he was UK site head and Scientific Director leading the development of their therapeutic antibody programs in immune-oncology and oncology.

Iain McInnes is one of the leading figures in global research into rheumatoid and psoriatic arthritis. He is Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology in the University of Glasgow. He has led numerous international clinical trials and pathogenesis investigation programmes in inflammatory arthritis, and his work has been hugely influential in driving new approaches and treatments for inflammatory diseases.

Iain is Vice-Principal and Head of College of Medical, Veterinary and Life Sciences at the University of Glasgow. His early studies identified the expression and functional importance of a number of cytokines in rheumatoid synovitis and have extended since to explore the pathways that drive inflammation in the skin and joints of people with psoriatic arthritis. Latterly he has developed a substantial programme investigating the mechanisms and treatment of common co-morbidities e.g. heart disease and lipid disorders, that afflict people with arthritis.

Professor McInnes has built an internationally recognised research programme that aims to understand the cellular and molecular pathways behind the development of inflammatory joint diseases. In particular, his research advances have provided a platform for major pharmaceutical companies to develop pre-clinical findings into clinical trials of innovative therapies.

Professor Iain McInnes was awarded the Sir James Black Prize Medal by the Royal Society of Edinburgh for his “outstanding contribution to the field of immunology”.

Séverine Vermeire is Head of the Department of Chronic Diseases & Metabolism (CHROMETA) at the KU Leuven. Séverine was appointed a Full Professor of gastroenterology at the KU Luven in 2003, and has been a University hospitals Luven board member since 2017.

She is actively involved as principal investigator in randomized clinical trials with new therapeutic compounds and has been lead investigator on several of these programs. Her scientific work resulted in more than 500 peer-reviewed articles and focuses on the role of the microbiome and genetic susceptibility in IBD and on identifying predictive signatures of treatment response. Dr. Vermeire participated in the International iCHOM consortium on development of Patient-Centered Outcomes for Inflammatory Bowel Disease. She was awarded several grants including an Advanced H2020-European Research Council (ERC) Grant (2016-2021). She served as president of the European Crohn’s and Colitis Organization (ECCO) from 2014-2016 and as president of the Belgian IBD Research & Development (BIRD) Group from 2011-2013.

Professor Peter Irving is a highly experienced consultant gastroenterologist renowned globally for his expertise in the field. With 25+ years of experience in gastroenterology, his specialist interest in inflammatory bowel disease (IBD) includes Crohn’s disease, ulcerative colitis, and irritable bowel syndrome as well as other types of functional gut disorders and endoscopy. Peter Irving is the lead for research in gastroenterology at Guy’s and St Thomas’ NHS Foundation Trust. He has led a wide variety of clinical trials in IBD and leads a research programme developing new treatments for IBD.

Ian Wilson is the former CEO and CTO of Edinburgh Molecular Imaging Ltd, leading the development of novel optical imaging agents to improve cancer detection and surgery, and lung disease. He has held several roles at GE Healthcare between 1996 and 2013, including Portfolio and Strategy Manager and Head of Biology, with responsibility for management of GE Healthcare’s Molecular Imaging Agent Portfolio, in Cardiovascular, Oncology and Neurology, and strategic and tactical oversight. He had responsibility for supporting efficacy and regulatory studies required for the approval of new imaging agents. At Xstrahl Ltd, as CTO &COO, he was responsible for the oversight of the Radiotherapy commercial operation and manufacture oversight, including new product development.